Today: 28 April 2026
Browse Category

Biotechnology 7 February 2026 - 28 April 2026

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Equities shares fell 9% Tuesday after first-quarter adjusted FFO dropped to $1.73 a share from $2.30 a year earlier and revenue declined to $671 million. The company lowered its 2026 occupancy and rental-rate assumptions but kept its adjusted FFO midpoint at $6.40. Net income rose to $358.9 million on a debt-repurchase gain. BNP Paribas Exane cut its price target to $44.
28 April 2026
····
Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International Group said Binance Coin (BNB) won 89.2% of a public vote and will be the first core digital asset in its new “Cryptocurrency Ark Plan.” BIYA shares surged 82% to $1.42 on Nasdaq, with trading volume near 184 million. The company plans an initial $1 million BNB purchase and will use trading gains for share buybacks. Recent filings indicate possible equity dilution as Baiya moves into crypto trading.
28 April 2026
··
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics will release Phase 3 data Monday from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema. The study enrolled 80 patients, testing a single 50 mg infusion against placebo. Intellia shares rose 19.3% after hours Friday ahead of the announcement. The company ended 2025 with $605.1 million in cash and expects it to last into late 2027.
25 April 2026
···
Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
21 April 2026
··
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
18 April 2026
··
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
15 April 2026
··
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals shares fell 2.9% to $8.50 premarket Monday after new clinical data on its hereditary angioedema drug pipeline. Interim results from the ALPHA-SOLAR study showed navenibart reduced mean monthly HAE attacks by 91% among 29 patients, with one discontinuation due to cancer. The company reaffirmed 2026 revenue guidance for ORLADEYO and expects a Phase 3 navenibart filing by late 2027.
2 March 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares traded near $0.42 in early premarket Tuesday after plunging about 80% when its main drug failed to meet the primary goal in a Phase 3 trial. The company said the study’s key endpoint improved by 13.3 meters but did not reach statistical significance. Analysts downgraded the stock and flagged risks around funding and regulatory timelines. Gossamer plans to meet the FDA and paused another study.
24 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL stock dives nearly 50% after UK Galleri trial misses key goal, raising FDA questions

GRAIL shares plunged nearly 50% to $51.00 after a UK trial showed its Galleri blood test missed the main goal of significantly improving early cancer detection. The study’s results complicate prospects for broad screening and reimbursement. Focus now shifts to U.S. regulators and Medicare-linked evidence. GRAIL reported Q4 revenue up 14% to $43.6 million and said its FDA approval submission is under review.
20 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche share price set for Monday test after MS drug fenebrutinib data lands

Roche said its experimental MS drug fenebrutinib met the main goal in a late-stage study for primary progressive multiple sclerosis, showing “non-inferiority” to Ocrevus but with more frequent, reversible liver enzyme elevations and a higher share of fatal cases. Roche shares last closed down 0.6% at 356.40 francs. Investors await Monday’s webcast for more data and filing plans.
8 February 2026
····
Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly shares climbed 3.7% in after-hours trading after the FDA announced plans to restrict GLP-1 ingredients in unapproved compounded drugs. Hims & Hers shares dropped nearly 12% after being referred for a Justice Department probe. Investors are watching for details on enforcement and pricing pressure as the market reacts to moves against copycat obesity drugs.
7 February 2026
···
1 2 3 … 16

Stock Market Today

  • Tuesday Options Surge in CIEN, SLS, and CR Highlights Market Interest
    April 28, 2026, 4:08 PM EDT. Noteworthy options activity hit Ciena Corp (CIEN), SELLAS Life Sciences (SLS), and Crane Co (CR) among Russell 3000 components on Tuesday. CIEN saw 14,348 contracts traded, about 54.9% of its average daily volume, with a surge in $550 strike calls expiring May 2026. SLS recorded 28,146 contracts, also 54.9% of daily volume, driven by $2 strike calls expiring September 2026. CR's options hit 2,834 contracts, 53.8% of daily volume, focused on $185 strike calls expiring June 2026. These volumes underline heightened interest in call options for those strikes. Options contracts represent the right to buy or sell stock at a fixed price before a set expiration, signaling bullish bets on price movements in these names.

Latest article

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

28 April 2026
Alexandria Real Estate Equities shares fell 9% Tuesday after first-quarter adjusted FFO dropped to $1.73 a share from $2.30 a year earlier and revenue declined to $671 million. The company lowered its 2026 occupancy and rental-rate assumptions but kept its adjusted FFO midpoint at $6.40. Net income rose to $358.9 million on a debt-repurchase gain. BNP Paribas Exane cut its price target to $44.
Sysco Stock Falls After Sales Miss: Restaurant Demand Weakness Tests $29 Billion Deal

Sysco Stock Falls After Sales Miss: Restaurant Demand Weakness Tests $29 Billion Deal

28 April 2026
Sysco shares dropped 3.6% Tuesday after quarterly sales missed analyst estimates, with revenue at $20.5 billion versus the expected $20.57 billion. Net earnings fell 15.2% to $340 million. The company reaffirmed its full-year profit outlook and highlighted growth in local restaurant sales. The update follows Sysco’s $29 billion deal to acquire Jetro Restaurant Depot.
Chip Stocks Drop as OpenAI Report Tests Nvidia, AMD and Broadcom AI Rally

Chip Stocks Drop as OpenAI Report Tests Nvidia, AMD and Broadcom AI Rally

28 April 2026
Nvidia, AMD, and Broadcom shares fell Tuesday after a Wall Street Journal report said OpenAI missed internal user and revenue targets, raising concerns about future AI spending. Nvidia dropped 0.9%, AMD lost 2.5%, and Broadcom slid 4.1% by mid-afternoon. OpenAI disputed claims of internal disagreement over spending. The selloff came ahead of major tech earnings reports.
Go toTop